nach oben

Erschienen in:

05.07.2023 | Brief Report

Polymyositis/dermatomyositis readmissions: analysis of the nationwide readmission database

verfasst von: Osahon Idolor, Ehizogie Edigin, Christopher Hino, Emily He, Janhavi Rao, Amaka Cynthia Ugoh, Precious Onobraigho, Eugene Omoike, Victory Okpujie, Chinedu James Ezeafulukwe, Precious Obehi Eseaton, Augustine Manadan, Christina Downey

Erschienen in: Clinical Rheumatology | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

There is a scarcity of national population-based studies on polymyositis (PM)/dermatomyositis (DM) readmissions in the USA. In this study, we aim to describe the rates, reasons for readmissions, and characteristics of readmissions for adults hospitalized for PM/DM in the USA.

Methods

We analyzed the 2018 Nationwide Readmissions Database (NRD). We included index hospitalizations for all adult DM/PM patients with a principal diagnosis of PM/DM using ICD-10 codes. We excluded elective and traumatic readmissions. Using a “rank” command in STATA, the most common specific principal diagnosis of readmissions was outlined. Chi-square tests were used to compare baseline characteristics between readmissions and index hospitalizations. STATA 16 was used for analysis.

Results

A total of 1610, 1286, and 842 index hospitalizations with a principal diagnosis of PM/DM, that were discharged alive, were included in the 30-, 90-, and 180-day readmission analysis, respectively. Among these, 193 (12%), 276 (21.5%), and 240 (28.5%) were readmitted within 30, 90, and 180 days, respectively. PM and sepsis were the most common reasons for reasons across the 3 timeframes. 30-day readmissions were responsible for an aggregate of 4.1 million US dollars in total hospital cost and 1518 hospital days in 2018. Compared to index hospitalizations, 30-day readmissions have higher Charlson Comorbidity Index scores, severe-extreme loss of function, obesity, and deep venous thrombosis.

Conclusion

About a third of PM/DM hospitalized patients are readmitted within 180 days. Readmissions constitute a significant economic burden to the health care system. PM and sepsis are the main reasons for readmissions.

Key points
• About a third of polymyositis (PM)/dermatomyositis (DM) hospitalized patients are readmitted within 180 days
• PM and sepsis are the main reasons for readmissions.
• Readmissions of PM/DM Patients constitute a significant economic burden to the health care system.
• Compared to index hospitalizations, 30-day readmissions have higher Charlson comorbidity index scores, severe-extreme loss of function, obesity, and deep venous thrombosis.

Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362(9388):971–982. https://doi.org/10.1016/S0140-6736(03)14368-1CrossRefPubMed

Wu C, Wang Q, He L, Yang E, Zeng X (2018) Hospitalization mortality and associated risk factors in patients with polymyositis and dermatomyositis: A retrospective case-control study. PLoS One 13(2):e0192491. https://doi.org/10.1371/journal.pone.0192491CrossRefPubMedPubMedCentral

Yazici Y, Kagen LJ (2002) Clinical presentation of the idiopathic inflammatory myopathies. Rheum Dis Clin North Am 28(4):823–832. https://doi.org/10.1016/s0889-857x(02)00023-6CrossRefPubMed

Cooper G, Stroehla B (2003) The epidemiology of autoimmune diseases. Autoimmunity Reviews 2:119–112. https://doi.org/10.1016/S1568-9972(03)00006-5CrossRefPubMed

Medsger TA Jr, Robinson H, Masi AT (1971) Factors affecting survivorship in polymyositis. A life-table study of 124 patients. Arthritis Rheum 14(2):249–258. https://doi.org/10.1002/art.1780140210CrossRefPubMed

Benbassat J, Gefel D, Larholt K, Sukenik S, Morgenstern V, Zlotnick A (1985) Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum 28(3):249–255. https://doi.org/10.1002/art.1780280303CrossRefPubMed

Marie I, Hachulla E, Chérin P, Hellot MF, Herson S, Levesque H, Hatron PY (2005) Opportunistic infections in polymyositis and dermatomyositis. Arthritis and rheumatism 53(2):155–165. https://doi.org/10.1002/art.21083CrossRefPubMed

Chen IJ, Tsai WP, Wu YJ, Luo SF, Ho HH, Liou LB, Chen JY, Kuo CF, Chang HC, Yang CH, Yu KH (2010) Infections in polymyositis and dermatomyositis: analysis of 192 cases. Rheumatology (Oxford) 49(12):2429–2437. https://doi.org/10.1093/rheumatology/keq279CrossRefPubMed

Carruthers EC, Choi HK, Sayre EC, Aviña-Zubieta JA (2016) Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. Ann Rheum Dis 75(1):110–116. https://doi.org/10.1136/annrheumdis-2014-205800CrossRefPubMed

10.

Li Y, Wang P, Li L, Wang F, Liu Y (2018) Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis. Ther Clin Risk Manag 14:157–165. https://doi.org/10.2147/TCRM.S157085CrossRefPubMedPubMedCentral

11.

Chung WS, Lin CL, Sung FC, Lu CC, Kao CH (2014) Increased risk of venous thromboembolism in patients with dermatomyositis/polymyositis: a nationwide cohort study. Thromb Res 134(3):622–626. https://doi.org/10.1016/j.thromres.2014.06.021CrossRefPubMed

12.

Zöller B, Li X, Sundquist J, Sundquist K (2012) Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 379(9812):244–249. https://doi.org/10.1016/S0140-6736(11)61306-8CrossRefPubMed

13.

Choi HK, Rho YH, Zhu Y, Cea-Soriano L, Aviña-Zubieta JA, Zhang Y (2013) The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann Rheum Dis 72(7):1182–1187. https://doi.org/10.1136/annrheumdis-2012-201669CrossRefPubMed

14.

Hotoleanu C (2020) Association between obesity and venous thromboembolism. Med Pharm Rep 93(2):162–168. https://doi.org/10.15386/mpr-1372CrossRefPubMedPubMedCentral

15.

Marie I, Maurey G, Hervé F, Hellot MF, Levesque H (2006) Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 155(4):714–721. https://doi.org/10.1111/j.1365-2133.2006.07390.xCrossRefPubMed

16.

Kapoor M, Spillane J, Englezou C, Sarri-Gonzalez S, Bell R, Rossor A, Manji H, Reilly MM, Lunn MP, Carr A (2020) Thromboembolic risk with IVIg: incidence and risk factors in patients with inflammatory neuropathy. Neurology 94(6):e635–e638. https://doi.org/10.1212/WNL.0000000000008742CrossRefPubMedPubMedCentral

17.

Bernatsky S, Panopalis P, Pineau CA, Hudson M, St Pierre Y, Clarke AE (2011) Healthcare costs of inflammatory myopathies. J Rheumatol 38(5):885–888. https://doi.org/10.3899/jrheum.101083CrossRefPubMed

18.

Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A (2019) Charlson Comorbidity Index: ICD-9 Update and ICD-10 Translation. Am Health Drug Benefits 12(4):188–197PubMedPubMedCentral

19.

Kichloo A, Edigin E, Jamal S, El-Amir Z, Aucar MI, Wani F, Eseaton PO, Annapureddy N, Cabling MG, Manadan AM (2022) Thirty-day hospital readmissions for acute gout in the United States: analysis of the nationwide readmission database. J Clin Rheumatol 28(2):e467–e472. https://doi.org/10.1097/RHU.0000000000001761CrossRefPubMed

20.

Kissel JT, Mendell JR, Rammohan KW (1986) Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 314(6):329–334. https://doi.org/10.1056/NEJM198602063140601CrossRefPubMed

21.

Benveniste O, Dubourg O, Herson S (2007) Nouvelles classifications et physiopathologie des myopathies inflammatoires [New classifications and pathophysiology of the inflammatory myopathies]. Rev Med Interne 28(9):603–612. https://doi.org/10.1016/j.revmed.2007.03.004CrossRefPubMed

Titel: Polymyositis/dermatomyositis readmissions: analysis of the nationwide readmission database
verfasst von: Osahon Idolor
Ehizogie Edigin
Christopher Hino
Emily He
Janhavi Rao
Amaka Cynthia Ugoh
Precious Onobraigho
Eugene Omoike
Victory Okpujie
Chinedu James Ezeafulukwe
Precious Obehi Eseaton
Augustine Manadan
Christina Downey
Publikationsdatum: 05.07.2023
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 10/2023
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-023-06690-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Polymyositis/dermatomyositis readmissions: analysis of the nationwide readmission database